Hypoxia-Conditioned Mesenchymal Stem Cell-Derived Exosomes Reduce NF-κB and STAT3 Gene Expression in a Type 2 Diabetes Mellitus Rats
DOI:
https://doi.org/10.59278/cbs.v5i14.114Keywords:
Type 2 Diabetes, Inflammation, NF-κB, STAT3, ExosomeAbstract
Background: Chronic low-grade inflammation is a key contributor to insulin resistance and progressive β-cell dysfunction in type 2 diabetes mellitus (T2DM). Nuclear factor-kappa B (NF-κB) and signal transducer and activator of transcription 3 (STAT3) are central regulators of inflammatory signaling implicated in metabolic dysfunction. Exosomes derived from hypoxia-conditioned mesenchymal stem cells (EH-MSCs) have emerged as promising cell-free therapeutics with potent immunomodulatory properties. This study evaluated the effects of EH-MSC-derived exosomes on pancreatic NF-κB and STAT3 gene expression in a streptozotocin–nicotinamide-induced rat model of T2DM. Methods: Umbilical cord-derived mesenchymal stem cells (UC-MSCs) were isolated, characterized according to International Society for Cellular Therapy criteria, cultured under 5% O₂ for 24 h, and exosomes were collected by tangential flow filtration. Twenty-eight male Wistar rats were randomly assigned to healthy control, T2DM+NaCl, T2DM+metformin, and T2DM+EH-MSC groups (n=7/group). Diabetes was induced using nicotinamide and streptozotocin. Metformin was administered orally for 14 days, whereas EH-MSC-derived exosomes (500 μL) were administered three times over 7 days. Pancreatic NF-κB and STAT3 mRNA expression was quantified by quantitative real-time PCR. Results: STZ induction successfully established T2DM, increasing fasting blood glucose from approximately 111 to 334 mg/dL. Diabetic rats exhibited marked upregulation of both NF-κB and STAT3 compared with healthy controls. EH-MSC-derived exosome treatment significantly reduced NF-κB and STAT3 expression (both p<0.05), restoring their expression toward physiological levels. In contrast, metformin produced only a modest reduction in NF-κB expression and a less pronounced effect on STAT3, indicating inferior suppression of inflammatory signaling compared with EH-MSC-derived exosomes. Conclusions: EH-MSC-derived exosomes effectively attenuated pancreatic inflammatory signaling by simultaneously suppressing NF-κB and STAT3 expression in experimental T2DM.
References
1. Antar SA, Ashour NA, Sharaky M, Khattab M, Ashour NA, Zaid RT, et al. Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments. Biomed Pharmacother. 2023 Dec 1;168:115734. doi:10.1016/j.biopha.2023.115734
2. Lu X, Xie Q, Pan X, Zhang R, Zhang X, Peng G, et al. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy. Signal Transduct Target Ther. 2024 Oct 2;9(1):262. doi:10.1038/s41392-024-01951-9
3. González P, Lozano P, Ros G, Solano F. Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections. Int J Mol Sci. 2023 May 27;24(11):9352. doi:10.3390/ijms24119352 PubMed PMID: 37298303; PubMed Central PMCID: PMC10253853.
4. Fayfman M, Hochberg I, Magee M, Rashied A, Chaudhry N, Jagannathan R, et al. A Real-World Study of Oral Antihyperglycemic Agents as Compared With Basal Insulin in Hospitalized Patients With Type 2 Diabetes. Endocr Pract. 2025 Oct 1;31(10):1239–46. doi:10.1016/j.eprac.2025.06.014
5. Gieroba B, Kryska A, Sroka-Bartnicka A. Type 2 diabetes mellitus – conventional therapies and future perspectives in innovative treatment. Biochem Biophys Rep. 2025 May 2;42:102037. doi:10.1016/j.bbrep.2025.102037 PubMed PMID: 40395625; PubMed Central PMCID: PMC12090304.
6. Mohallem R, Aryal UK. Regulators of TNFα mediated insulin resistance elucidated by quantitative proteomics. Sci Rep. 2020 Nov 30;10(1):20878. doi:10.1038/s41598-020-77914-1
7. Zhao M, Chauhan P, Sherman CA, Singh A, Kaileh M, Mazan-Mamczarz K, et al. NF-κB subunits direct kinetically distinct transcriptional cascades in antigen receptor-activated B cells. Nat Immunol. 2023 Sep;24(9):1552–64. doi:10.1038/s41590-023-01561-7
8. Giridharan S, Srinivasan M. Mechanisms of NF-κB p65 and strategies for therapeutic manipulation. J Inflamm Res. 2018 Oct 30;11:407–19. doi:10.2147/JIR.S140188 PubMed PMID: 30464573; PubMed Central PMCID: PMC6217131.
9. Chattopadhyay S, Rajendran RL, Chatterjee G, Reyaz D, Prakash K, Hong CM, et al. Mesenchymal stem cell-derived exosomes: A paradigm shift in clinical therapeutics. Exp Cell Res. 2025 Jul 1;450(1):114616. doi:10.1016/j.yexcr.2025.114616
10. Franco JP, Jaraba-Alvarez W, Blanquiceth Y, Bedoya A, Ortiz S, Uscanga A, et al. Hypoxic Culture vs. Normoxia Standard Culture in Umbilical Cord Mesenchymal Stem Cells: Enhanced Exosomal Yield and Unique Regenerative Signature. Cytotherapy. 2025 May 1;Abstracts of the 31st Annual ISCT Meeting May 7-May 10, 202527(5, Supplement):S86. doi:10.1016/j.jcyt.2025.03.164
11. Jiao YR, Chen KX, Tang X, Tang YL, Yang HL, Yin YL, et al. Exosomes derived from mesenchymal stem cells in diabetes and diabetic complications. Cell Death Dis. 2024 Apr 17;15(4):271. doi:10.1038/s41419-024-06659-w.
12. Dominici M, Blanc K Le, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8(4):315–317.
13. Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2018;7(1).
14. Irawan RC, Putra A, Setyo T, Ghaisani SS, Hidayah N. Secretome hypoxia-mesenchymal stem cells decrease tumor necrosis factor-α and interleukin-18 in kidney of type 2 diabetes mellitus model rats. Universa Medicina. 2023 Dec 23;42(3):320-8.
15. Yap SK, Tan KL, Abd Rahaman NY, Saulol Hamid NF, Ooi DJ, Tor YS, Daniel Looi QH, Stella Tan LK, How CW, Foo JB. Human umbilical cord mesenchymal stem cell-derived small extracellular vesicles ameliorated insulin resistance in type 2 diabetes mellitus rats. Pharmaceutics. 2022 Mar 16;14(3):649.
16. Zhang D, Xiao W, Liu C, Wang Z, Liu Y, Yu Y, Jian C, Yu A. Exosomes derived from adipose stem cells enhance bone fracture healing via the activation of the Wnt3a/β-catenin signaling pathway in rats with type 2 diabetes mellitus. International journal of molecular sciences. 2023 Mar 2;24(5):4852.
17. Wang Z, Ni X, Zhang L, Sun L, Zhu X, Zhou Q, Yang Z, Yuan H. Toll-like receptor 4 and inflammatory micro-environment of pancreatic islets in type-2 diabetes mellitus: a therapeutic perspective. Diabetes, Metabolic Syndrome and Obesity. 2020 Nov 10:4261-72.
18. Chen MY, Meng XF, Han YP, Yan JL, Xiao C, Qian LB. Profile of crosstalk between glucose and lipid metabolic disturbance and diabetic cardiomyopathy: Inflammation and oxidative stress. Frontiers in endocrinology. 2022 Sep 15; 13:983713.
19. Zhang S, Zhang ZY, Tang RN, Zhang K, Fu Y, Tian H, Ma J, Jin Y, Zheng CX, Sui BD. Mesenchymal stem cell-derived extracellular vesicles in the treatment of type 2 diabetes and its complications: current progress and future directions. Stem Cell Research & Therapy. 2026 Mar 29.
20. Rogero MM, Calder PC. Obesity, inflammation, toll-like receptor 4 and fatty acids. Nutrients. 2018 Mar 30;10(4):432.
21. Utami A, Putra A, Wibowo JW, Amalina ND, Satria Irawan RC. Hypoxic secretome mesenchymal stem cells inhibiting interleukin-6 expression prevent oxidative stress in type 1 diabetes mellitus. Medicinski glasnik. 2023 Aug 1;20(2):148.
22. Pulido-Escribano V, Torrecillas-Baena B, Dorado G, Gálvez-Moreno MÁ, Camacho-Cardenosa M, Casado-Díaz A. Combination of biomaterials and extracellular vesicles from mesenchymal stem-cells: new therapeutic strategies for skin-wound healing. Applied Sciences. 2023 Feb 20;13(4):2702.
23. Gurunathan S, Kang MH, Kim JH. A comprehensive review on factors influences biogenesis, functions, therapeutic and clinical implications of exosomes. International journal of nanomedicine. 2021 Feb 17:1281-312.
24. Putra A, Alif I, Prasetio A, Prawitasari S. Comparison of two tangential flow filtration methods in isolating cd63+/CD9+ mesenchymal stem cell exosome. International Journal of Cell and Biomedical Science. 2023 Sep 20;2(4):147-52.
25. Sun Y, Shi H, Yin S, Ji C, Zhang X, Zhang B, Wu P, Shi Y, Mao F, Yan Y, Xu W. Human mesenchymal stem cell derived exosomes alleviate type 2 diabetes mellitus by reversing peripheral insulin resistance and relieving β-cell destruction. ACS nano. 2018 Jul 27;12(8):7613-28.
26. Che Z, Yan W, Zhao Q. Extracellular vesicles in the mesenchymal stem cell/macrophage axis: potential targets for inflammatory treatment. International Journal of Molecular Sciences. 2025 Mar 20;26(6):2827.
27. Yap SK, Tan KL, Abd Rahaman NY, Saulol Hamid NF, Ooi DJ, Tor YS, Daniel Looi QH, Stella Tan LK, How CW, Foo JB. Human umbilical cord mesenchymal stem cell-derived small extracellular vesicles ameliorated insulin resistance in type 2 diabetes mellitus rats. Pharmaceutics. 2022 Mar 16;14(3):649.
28. Moshapa FT, Riches-Suman K, Palmer TM. Therapeutic targeting of the proinflammatory IL‐6‐JAK/STAT signalling pathways responsible for vascular restenosis in type 2 diabetes mellitus. Cardiology research and practice. 2019;2019(1):9846312.
29. Yang M, Tian M, Zhang X, Xu J, Yang B, Yu J, Li F, Li Y, Li S, Li X. Role of the JAK2/STAT3 signaling pathway in the pathogenesis of type 2 diabetes mellitus with macrovascular complications. Oncotarget. 2017 Jun 16;8(57):96958.
30. Onyango AN. Cellular stresses and stress responses in the pathogenesis of insulin resistance. Oxidative medicine and cellular longevity. 2018;2018(1):4321714.
31. Matsuda T. The physiological and pathophysiological role of IL-6/STAT3-mediated signal transduction and STAT3 binding partners in therapeutic applications. Biological and Pharmaceutical Bulletin. 2023 Mar 1;46(3):364-78.
32. Samad MA, Ahmad I, Hasan A, Alhashmi MH, Ayub A, Al‐Abbasi FA, Kumer A, Tabrez S. STAT3 signaling pathway in health and disease. MedComm. 2025 Apr;6(4):e70152.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 International Journal of Cell and Biomedical Science

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.









